The Benefits Of Low Dose Naltrexone

Low dose naltrexone (LDN) is a medication that has been gaining popularity in recent years due to its proven benefits in the treatment of various conditions.

What is Naltrexone?

Naltrexone is an opioid antagonist that has been approved by the FDA for the treatment of opioid dependence and alcohol addiction at higher doses (50 mg/day).

What is Low Dose Naltrexone?

At low doses (typically 1.5 to 4.5 mg/day), Naltrexone has been found to have different effects on the body that have been shown to be very beneficial for a range of many conditions.

What conditions can Low Dose Naltrexone (LDN) help?

LDN has been shown to revolutionize treatment for disorders including PTSD, chronic pain, IBD, Lyme disease, Autoimmune diseases including Multiple sclerosis, Autism, Depression, Dermatologic conditions, Viral infections, Long COVID, mold toxicity, cancer, and even help to improve longevity by decreasing inflammation and enhancing mitochondrial function.

One of the main mechanisms by which LDN works is by modulating the immune system. It has been found to increase the levels of endogenous opioids, which can have anti-inflammatory effects and promote tissue repair. Additionally, LDN has been shown to reduce the activity of certain immune cells, such as microglia, that are involved in chronic inflammation and neurodegenerative diseases.

Some of the conditions that LDN has been studied for include multiple sclerosis, Crohn’s disease, fibromyalgia, and chronic pain. In a randomized controlled trial of 40 patients with multiple sclerosis, LDN was found to improve symptoms and quality of life compared to placebo (Cree et al., 2010). Similarly, in a small study of 17 patients with Crohn’s disease, LDN was found to improve symptoms and reduce the need for medication (Smith et al., 2011). LDN has also been found to be effective in reducing pain and improving mood in patients with fibromyalgia (Younger et al., 2013).

LDN has also been studied for its potential anticancer effects. It has been found to inhibit the growth of cancer cells in vitro and in animal models, and there are some case reports of LDN being used successfully in cancer patients (Donahue et al., 2018). However, more research is needed to fully understand the full potential LDN has as a cancer treatment.

According to the LDN Research Trust,  LDN has been found to be effective when treating patients suffering from long COVID ( various clustered symptoms that may occur and change over time after an individual had  COVID-19). Issues can range from chronic pain, POTS, dyspnea, and persistent fatigue / chronic fatigue syndrome. There is clinical evidence that shows LDN is a safe and effective long-term treatment option for patients suffering from long COVID. If you are struggling with long COVID, make an appointment with Abigail Butterfield, Nurse Practitioner at Renew Health & Wellness in Apollo Beach, Florida to see if the use of LDN can help you reach your wellness goals!

Overall, LDN is a safe and well-tolerated medication with many potential benefits for a range of conditions. However, as with any medication, it is important to consult with a healthcare provider before starting LDN, as it may interact with other medications or have contraindications for certain conditions. Schedule an appointment with Abigail Butterfield, APRN to discuss if LDN is an appropriate treatment option for you!

References:

  • Cree, B. A. C., Kornyeyeva, E., Goodin, D. S., & Pilot Study Investigators. (2010). Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology, 68(2), 145–150. https://doi.org/10.1002/ana.22006
  • Smith, J. P., Stock, H., Bingaman, S., & Mauger, D. (2011). Low-dose naltrexone therapy improves active Crohn’s disease. American Journal of Gastroenterology, 106(10), 1805–1812. https://doi.org/10.1038/ajg.2011.155
  • Younger, J., Parkitny, L., & McLain, D. (2013). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 32(4), 451–455. https://doi.org/10.1007/s10067-013-2434-8
  • Donahue, R. N., McLaughlin, P. J., Zagon, I. S., & Low Dose Naltrexone (LDN) Collaborative Group. (2018). The promise of low dose naltrexone therapy in cancer. International Immunopharmacology, 56,
  • Elsegood, L. (2022). The ldn book 3. LDN Research Trust.